S. 4338 · 117th Congress

Increasing Transparency in Generic Drug Applications Act

Stage
In committee
Introduced
2022-05-26
Latest action
2022-05-26 · Introduced in Senate

Summary

Increasing Transparency in Generic Drug Applications Act

This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).